KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 2243 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. PMID 34819997 · Ther Adv Med Oncol · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US. PMID 34778047 · Front Oncol · 2021 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. PMID 34745955 · Front Oncol · 2021 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. PMID 34733356 · Ther Adv Urol · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. PMID 34721672 · Ther Adv Med Oncol · 2021 While the study is oncology, human, randomized, phase 3, and time-to-event, it fails the drug-intervention criterion. The abstract mentions a 'randomized controlled phase 3 trial cohort' as part of validation but does not specify any drug intervention (e.g., chemotherapy, targeted therapy, immunotherapy). It appears to be a retrospective analysis of clinical records, not a report of a specific drug trial. Therefore, it is not eligible for inclusion in an oncology Kaplan-Meier digitization cohort focused on drug intervention trials.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. PMID 34692470 · Front Oncol · 2021 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. PMID 34660302 · Front Oncol · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. PMID 34616855 · J Health Econ Outcomes Res · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. PMID 34616296 · Front Pharmacol · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients with Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study. PMID 34611424 · Int J Gen Med · 2021 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Role of immunotherapy in localized muscle invasive urothelial cancer. PMID 34567274 · Ther Adv Med Oncol · 2021 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. PMID 34557402 · Front Oncol · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. PMID 34513709 · Front Oncol · 2021 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. PMID 34484242 · Front Immunol · 2021 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer. PMID 34393513 · Cancer Manag Res · 2021 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 2 Figure · 2 Panel · risk unclear
Can Polymetastatic Disease Be ARRESTed Using SABR? A Dosimetric Feasibility Study to Inform Development of a Phase 1 Trial. PMID 34278053 · Adv Radiat Oncol · 2021 The record describes a dosimetric feasibility study and simulation to inform a future Phase 1 trial. It is not a report of an original, completed Phase III/IIIb or Phase II/III randomized trial. While it mentions randomized trials in the background, the study itself is non-randomized, lacks drug intervention, and presents no efficacy results.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PMID 42485480 PMID 42485480 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42485474 PMID 42485474 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42485473 PMID 42485473 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42479860 PMID 42479860 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42330139 PMID 42330139 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42190031 PMID 42190031 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42184309 PMID 42184309 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42160650 PMID 42160650 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42154951 PMID 42154951 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42154934 PMID 42154934 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42150011 PMID 42150011 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42127237 PMID 42127237 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 42118866 PMID 42118866 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41628289 PMID 41628289 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41592168 PMID 41592168 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41529132 PMID 41529132 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41474856 PMID 41474856 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41468482 PMID 41468482 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41411457 PMID 41411457 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41401269 PMID 41401269 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41066608 PMID 41066608 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41021730 PMID 41021730 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 41021721 PMID 41021721 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 40902027 PMID 40902027 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 40857365 PMID 40857365 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 39466929 PMID 39466929 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -
PMID 36548455 PMID 36548455 · - · - PubMed 检索返回该 PMID,但 EFetch 未提供可解析的论文元数据。
S B
严格 v3 独有 needs_reviewpubmed_metadata_unavailable pending 0 Figure · 0 Panel · risk -